Want to see AIM full AI Analyst Report?
AIM Stock Chart & Stats
$1.25
>-$0.01(-4.03%)
At close: 4:00 PM EST
$1.25
>-$0.01(-4.03%)
Day’s Range― - ―
52-Week Range$0.21 - $20.33
Previous CloseN/A
Volume272.06K
Average Volume (3M)39.50M
Market Cap
$8.04M
Enterprise Value$119.42K
Total Cash (Recent Filing)$5.88M
Total Debt (Recent Filing)$4.57M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 18, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding27,724,245
10 Day Avg. Volume1,013,981
30 Day Avg. Volume39,498,775
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit-0.96
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside320.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Listing Compliance & Capital AccessRestoring NYSE American compliance via financings materially reduces near-term delisting risk and preserves a key public market access channel. This durable improvement supports ongoing institutional capital access, governance signaling, and the company’s ability to fund multi-stage clinical programs over the coming quarters.
Promising Lead Asset (Ampligen) Clinical MomentumClinical signals and KOL engagement for Ampligen in pancreatic cancer, plus ongoing Phase 2 work with an approved checkpoint inhibitor, meaningfully de-risks the program if replicated. Durable clinical progress and peer-reviewed publications can create an enduring competitive position in a high-unmet-need oncology niche.
Low Reported DebtModest reported debt reduces immediate solvency pressure and interest burden, giving management flexibility to allocate capital to R&D. Structurally, low leverage improves optionality for strategic financings or partnerships without heavy near-term repayment constraints.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates structural funding needs to advance clinical programs. Over a multi-quarter horizon this necessitates repeated external financing, constrains investment optionality, and makes program timelines sensitive to capital availability regardless of scientific progress.
Minimal Commercial RevenueWith essentially no commercial sales and deeply negative margins, the business lacks operating cash generation to self-fund development. This structural revenue shortfall means long-term viability depends on successful clinical outcomes, partnerships, or continuous capital markets access rather than internal cash flow.
Reliance On Equity/Warrant FinancingsFrequent reliance on inducement exercises, registered directs and new warrant classes is a durable dilution vector that can compress shareholder value and complicate future capital raises. Dependence on equity-linked financing increases sensitivity to market conditions and can pressure long-term investor alignment.
AIM ImmunoTech News
AIM FAQ
What was Aim Immunotech Inc.’s price range in the past 12 months?
Aim Immunotech Inc. lowest stock price was $0.21 and its highest was $20.33 in the past 12 months.
What is Aim Immunotech Inc.’s market cap?
Aim Immunotech Inc.’s market cap is $8.04M.
When is Aim Immunotech Inc.’s upcoming earnings report date?
Aim Immunotech Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.
How were Aim Immunotech Inc.’s earnings last quarter?
Currently, no data Available
Is Aim Immunotech Inc. overvalued?
According to Wall Street analysts Aim Immunotech Inc.’s price is currently Undervalued.
Does Aim Immunotech Inc. pay dividends?
Aim Immunotech Inc. pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on Aim Immunotech Inc. dividends here
What is Aim Immunotech Inc.’s EPS estimate?
Aim Immunotech Inc.’s EPS estimate is -0.17.
How many shares outstanding does Aim Immunotech Inc. have?
Aim Immunotech Inc. has 27,724,245 shares outstanding.
What happened to Aim Immunotech Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aim Immunotech Inc.?
Currently, no hedge funds are holding shares in AIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aim Immunotech Inc.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
AIM Stock 12 Month Forecast
Average Price Target
$5.25
▲(320.00% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
0.10% Mutual Funds
<0.01% Other Institutional Investors
99.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---